Background. Influenza B virus strains in trivalent influenza vaccines are frequently mismatched to the circulating B strains, but the population-level impact of such mismatches is unknown. We assessed the impact of vaccine mismatch on the epidemiology of influenza B during 12 recent seasonal outbreaks of influenza in Finland.
Since the mid-1980s, 2 antigenically distinct lineages of influenza B viruses (B/Victoria-like and B/Yamagatalike) have been circulating globally, causing disease in humans [1] . The divergence of influenza B viruses into 2 lineages has posed problems for the production of seasonal influenza vaccines, which have traditionally contained the 2 circulating influenza A strains, A(H1N1) and A(H3N2), but only a single B strain. During the past decade, selecting the correct B component of the trivalent influenza vaccine has proved particularly challenging, and lineage-level mismatches between the vaccine and circulating strains of B viruses have occurred during approximately half of the seasons [2] . The level of cross-protection between the 2 B lineages is not well known, but it is assumed to be low [3] [4] [5] [6] . As a consequence, a lineage-level mismatch between the vaccine and the predominant circulating B strains is likely to reduce substantially the clinical effectiveness of the trivalent influenza vaccine during annual outbreaks.
In recent years, several studies have elucidated the previously poorly recognized clinical importance of influenza B viruses, resulting in increased interest in the production of quadrivalent vaccines that include both lineages of influenza B viruses [2, [7] [8] [9] [10] [11] . Although the first quadrivalent influenza vaccines were already introduced in the United States in the autumn of 2013, such vaccines are not yet available in most other parts of the world, and even in the United States the true clinical benefit afforded by these vaccines remains uncertain [12] . We designed this study to assess the overall impact of lineage-level vaccine mismatch against influenza B viruses during 12 influenza seasons in Finland.
METHODS

Study Design
We analyzed all available nationwide data on virologically confirmed seasonal influenza infections in all age groups in Finland between 1 July 1999 and 30 June 2012. We excluded the pandemic A(H1N1) season of 2009-2010 (defined as 1 July 2009 through 30 June 2010, for the purpose of this study) from the analyses because the focus of this study was on seasonal influenza, and the numbers of viral specimens obtained during the pandemic season were disproportionately high compared with other seasons. Hence, the total study period consisted of 12 seasonal outbreaks of influenza A and B viruses.
We analyzed all data in different age groups, categorizing children into 4 groups (0-4, 5-9, 10-14, and 15-19 years) and adults into 6 groups (20-29, 30-39, 40-49, 50-59, 60-69, and ≥70 years). Because the main purpose of this study was to determine the impact of vaccine-mismatched influenza B infections, we made no attempt to estimate the relative impact of A(H1) and A(H3) infections during the study period.
Sources of Data
We extracted the numbers of patients with virologically confirmed influenza infections during each season of the study period from the Statistical Database of the Infectious Diseases Register maintained by the National Institute for Health and Welfare, Finland. This register has been operational since 1995, and it contains monthly data on all influenza viruspositive specimens (A, B, or untyped) reported by diagnostic laboratories and practicing physicians from all regions of the country. These register data provide the most comprehensive estimate of the annual incidence of influenza A and B infections in different age groups in Finland.
We collected detailed data on the circulation of different lineages of influenza B viruses during each season in Finland from the National Influenza Center, National Institute for Health and Welfare. The National Influenza Center receives clinical specimens for sequencing and detailed identification of influenza viruses from patients with influenza-like illness seen in several sentinel clinics and collaborating medical centers in different parts of the country. Data on different lineages of influenza B viruses were available in electronic files since 1999. To ensure consistency in the data to be analyzed, we included only data from 1999 onward in this analysis. This decision was also supported by the fact that lineage-level vaccine mismatch against B viruses has been a particular problem during the past decade [2] . We estimated the extent of vaccine mismatch against influenza B viruses by comparing the known B antigens contained in the vaccine and the proportions of different lineages of B viruses circulating in Finland during each season of the study. For the season of 2003-2004, when influenza B viruses were very infrequently detected in Finland and other European countries, we based our estimation of vaccine mismatch against influenza B viruses on European-level data provided by the European Influenza Surveillance Scheme [13] . We rounded the estimated proportions of matched and mismatched influenza B viruses to the nearest 5% in the calculations.
Because this study was based solely on registry data available from the National Institute for Health and Welfare and openly accessible data from the National Infectious Diseases Register in Finland, it was not subject to ethics committee approval.
Statistical Analysis
When calculating the adjusted numbers of influenza A and B cases for each season, we allocated untyped viruses into influenza A and B viruses using the observed proportions of confirmed type A and B viruses during that season. We calculated 95% confidence intervals (CIs) for the proportions by the exact (Clopper-Pearson) method with the use of StatsDirect statistical software, version 2.7.9.
RESULTS
Overall Reporting of Influenza A and B Virus Infections
During the 12 seasons of this study, a total of 34 788 virologically confirmed influenza cases were reported to the Infectious Diseases Register in Finland (Table 1) . Of all influenza virus-positive patients, 15 055 (43.3%) were 0-19 years of age, 13 100 (37.7%) were 20-49 years of age, and 6633 (19.1%) were ≥50 years of age. Across all seasons, influenza A accounted for 23 714 (74.0%) and influenza B for 8317 (26.0%) of the 32 031 typed viruses; 2757 (7.9% of all) viruses remained untyped. Following allocation of these untyped viruses into influenza A and B viruses according to the observed proportions of confirmed type A and B viruses during each season, the estimated total numbers of influenza A and B infections were 25 795 and 8993, respectively. 
Influenza B Lineage-Level Mismatch
We assessed the extent of lineage-level mismatch between the vaccine and circulating strains of influenza B viruses for each season by using information about the genetic and/or antigenic characteristics of circulating influenza B strains (Table 2) . We observed a predominantly good match (90%-100%) between the vaccine B strain and the circulating influenza B viruses in (Table 3) . Altogether, these opposite-lineage influenza B infections accounted for 10.8% (95% CI, 10.4-11.1) of all influenza infections during the study period, with the corresponding proportions ranging from 0.0% to 49.6% during individual influenza seasons.
During the entire study period, the overall proportion of influenza B infections among all influenza infections was highest years. Among all B viruses, the relative proportions of strains representing the genetic lineage opposite to the vaccine lineage ranged between 34.9% and 46.6% in different age groups.
DISCUSSION
Using a large, representative nationwide database over 12 recent epidemic seasons, we found that approximately 40% of all influenza B viruses causing infections in the population represented the other genetic lineage than the one included in the trivalent influenza vaccines. Overall, these mismatched influenza B infections accounted for approximately 10% of all influenza illnesses in the population. The impact of the vaccine mismatch was greatest among children and adolescents, among whom up to 17% of all influenza illnesses were due to influenza B viruses of the lineage that was not contained in the vaccine. To our knowledge, this is the first study to provide a robust, population-level estimate of the impact of the lineage-level mismatch of the B component in seasonal influenza vaccines. A particular strength of our study is that we were able to combine the numbers of type-specific influenza infections with locally derived data on the circulation of different lineages of influenza B viruses during each season. Because the relative proportions of different types and subtypes of influenza viruses vary substantially between different countries and regions during any given season, the use of influenza B strain-specific data arising from some other region than that of the population under study would likely reduce the accuracy of the estimates. Furthermore, our 12-year study period included 7 seasons with good lineagelevel match and only 4 seasons with clear lineage-level mismatch of the influenza B vaccine component, which implies that the results were not biased by primarily including only those seasons when lineage-level mismatch between the vaccine and circulating strains of influenza B viruses occurred.
The overall importance of influenza B viruses is underscored by our finding that 26% of all virologically confirmed influenza illnesses in the population during the 12 seasons were caused by B viruses. The relative proportion of influenza B viruses was greatest (approximately 40%) in children 5-14 years of age, which is in agreement with previous studies in other geographic areas [14] . A logical implication of this finding is that children and adolescents might benefit most from the addition of a second influenza B strain to the seasonal influenza vaccine. For example, if one made conservative assumptions that (1) 15% of all influenza illnesses in children were caused by lineage-level mismatched B viruses, (2) the efficacy of influenza vaccine was a modest 70% against all circulating strains, and (3) the level of vaccine-induced cross-protection between the 2 B lineages was 30% [3] , a total of 640 per 1000 cases of influenza could be prevented by the use of trivalent vaccine and 700 per 1000 cases by the use of quadrivalent vaccine (6% absolute reduction). The additional 60 per 1000 cases that could be prevented with a quadrivalent vaccine would represent a 17% relative reduction of influenza illnesses in children when compared with a trivalent vaccine (60 of 360 per 1000 cases not preventable with a trivalent vaccine). The reductions would be even greater if the efficacy of the vaccine were higher and/or the level of cross-protection lower than what was assumed in the abovementioned example.
Influenza B viruses are generally underestimated because they are thought to cause less severe illnesses than A viruses. However, although A(H3N2) subtypes have been associated with the greatest numbers of deaths and hospitalizations, the corresponding figures related to influenza B viruses have exceeded those of seasonal A(H1N1) viruses circulating prior to the 2009 pandemic [15, 16] . The histological features of fatal influenza B infections are similar to those of influenza A infections [9] , and comparative clinical studies have demonstrated that influenza B infections are indistinguishable from influenza A infections [17] [18] [19] [20] [21] . Particularly in children, the conventional concept of influenza B viruses causing a milder disease may be seriously confounded by age because children with influenza B infections are generally older than those with influenza A infections [14, 17, 18, 22] . When adjusted for age, the clinical presentation of influenza B appears to be comparable to that of influenza A [23] .
Some limitations of our study require consideration. First, it is obvious that the numbers of influenza cases reported to the Infectious Diseases Register represented only a small proportion of all influenza illnesses in the country because virologic confirmation of influenza is not routinely performed, especially among outpatients. However, the narrow confidence intervals for the observed proportions of influenza A and B viruses indicate that the numbers of viruses identified were adequate for reliable calculations. Second, the frequency of sampling for viral detection may have varied between different areas and settings. Although this may have brought some imbalance to the register data, our analyses were mainly based on the relative prevalence of influenza A and B viruses during each season, and it is unlikely that any sampling-related variation could have favored either virus type and thus biased the results. Third, the sentinel clinics that provided the National Influenza Center with clinical specimens for the identification of influenza viruses may not have closely represented the population demographics. However, even if true, this could have affected the results in the direction of substantial overestimation of the impact of mismatched B viruses only during seasons with predominant vaccine mismatch and considerable influenza B activity (2005-2006, 2007-2008, and 2008-2009 ). During those seasons, the mismatch between the vaccine strain and circulating influenza B viruses was virtually identical in Finland and the rest of Europe [2] .
Our findings provide strong support for the inclusion of both influenza B lineages in seasonal influenza vaccines. The substantial impact of lineage-level mismatched influenza B viruses is in agreement with recent estimates which have indicated that switching from trivalent to quadrivalent influenza vaccines would result not only in reductions in influenza-related illnesses, hospitalizations, and deaths, but also in substantial cost savings to society [24, 25] .
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